SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Gillmore JD, Hawkins PN, Pepys MB. Amyloidosis: a review of recent diagnostic and therapeutic developments [review]. Br J Haematol 1997; 99: 24556.
  • 2
    Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M, et al, and the Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis With Concomitant Therapy Study Group. Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. Lancet 1999; 354: 19329.
  • 3
    Gottenberg JE, Merle-Vincent F, Bentaberry F, Allanore Y, Berenbaun F, Fautrel B, et al. Anti–tumor necrosis factor α therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy. Arthritis Rheum 2003; 48: 201924.
  • 4
    Elkayam O, Hawkins PN, Lachmann H, Yaron M, Caspi D. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. Arthritis Rheum 2002; 46: 25713.
  • 5
    FDA. Safety update on TNF-α antagonists: infliximab and etanercept. FDA, Center for Biologics Evaluation and Research; 2001. URL: http://www.fda.gov/ohrms/dockets/ac/01/ briefing/3779b2.htm.
  • 6
    Ostuni P, Botsios C, Punzi L, Sfriso P, Todesco S. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate [letter]. Ann Rheum Dis 2003; 62: 6867.
  • 7
    Oniankitan O, Duvoux C, Challine D, Mallat A, Chevalier X, Pawlotsky JM, et al. Infliximab therapy for rheumatic diseases in patients with chronic hepatitis B or C. J Rheumatol 2004; 31: 1079.
  • 8
    Michel M, Duvoux C, Hezode C, Cherqui D. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Still's disease. J Rheumatol 2003; 30: 16245.